Skip to Content
Merck
All Photos(1)

Documents

SML0881

Sigma-Aldrich

Rivastigmine tartrate

≥98% (HPLC)

Synonym(s):

ENA-713, Ethylmethyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester, N-Ethyl-N-methyl-carbamic acid 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester tartrate, S-Rivastigmine tartrate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C14H22N2O2 · C4H6O6
CAS Number:
129101-54-8
Molecular Weight:
400.42
UNSPSC Code:
12352200
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H2O: 15 mg/mL, clear

storage temp.

2-8°C

InChI

1S/C14H22N2O2.C4H6O6/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4;5-1(3(7)8)2(6)4(9)10/h7-11H,6H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t11-;1-,2-/m00/s1

InChI key

GWHQHAUAXRMMOT-RWALOXMOSA-N

Looking for similar products? Visit Product Comparison Guide

General description

Rivastigmine tartrate is a cholinesterase inhibitor. It is also called as exelon.

Application

Rivastigmine tartrate has been used in cholinesterase inhibition assay.

Biochem/physiol Actions

Rivastigmine is an orally available, brain penetrant, reversible cholinesterase inhibitor that enhances cognitive function in patients with Alzheimer′s and Parkinson′s diseases. Rivastigmine inhibits both butyrylcholinesterase and acetylcholinesterase.
Rivastigmine tartrate is used to treat Alzheimer′s disease. It helps to improve thinking ability. It helps to increase cholinergic function by inhibiting acetylcholinesterase.

Features and Benefits

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Acetylcholine Synthesis and Metabolism page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Pictograms

Skull and crossbonesEnvironment
GHS06,GHS09

Signal Word

Danger

Hazard Statements

H300,H411

Hazard Classifications

Acute Tox. 2 Oral - Aquatic Chronic 2

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The Complete Pill Guide, 1151-1151 (2003)
2, 4-Disubstituted quinazolines as amyloid-β aggregation inhibitors with dual cholinesterase inhibition and antioxidant properties: Development and structure-activity relationship (SAR) studies.
Mohamed T and Rao PPN
European Journal of Medicinal Chemistry, 126, 823-843 (2017)
Desk Reference of Clinical Pharmacology, Second Edition, 824-824 (2007)
Emily J Henderson et al.
BMC neurology, 13, 188-188 (2013-12-05)
Gait impairment is common in people with Parkinson's disease. There is a lack of effective interventions to target this debilitating complication and therefore a need to identify new therapeutic options. An underlying cholinergic deficit contributes to both the gait and
Martin R Farlow et al.
CNS neuroscience & therapeutics, 19(10), 745-752 (2013-08-09)
The 24-week, prospective, randomized, double-blind ACTION study investigated the efficacy, safety, and tolerability of 13.3 versus 4.6 mg/24 h rivastigmine patch in patients with severe Alzheimer's disease (AD). Patients had probable AD and Mini-Mental State Examination scores ≥3-≤12. Primary outcome
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service